Diabetes mellitus is the most common disorder of the endocrine pancreas in dogs and cats. The incidence in dogs is approximately 0.13%, and the incidence in cats is approximately 0.5%, depending on the study population, and is influenced by geographical location and type of veterinary practice (referral or primary accession).
Diabetes mellitus is a disease of middle aged to older companion animals, with peak prevalence of 7-12 years of age in dogs, and 10 – 13 years in cats. Intact female dogs, and male cats, are predisposed. Various breeds of cat and dog are overrepresented, and predisposed breeds vary with geographic area. For example, in the USA, dog breeds at increased risk include miniature Schnauzer, Samoyed, and miniature poodle, whereas in the UK, in addition to Miniature Schnauzer and Samoyed, breeds more commonly seen include Tibetan, Cairn, Border and Yorkshire Terriers and Labrador retrievers. In cats, Burmese are overrepresented in Australia, New Zealand and UK, and in USA, Maine coon, domestic longhair, Russian Blue and Siamese. Norwegian forest cats are at increased risk in Scandinavia.
Type 1 diabetes is a result of immune-mediated β-cell destruction, usually leading to an absolute insulin deficiency. The majority of neutered diabetic dogs have type 1 diabetes, but this form appears to be very rare in cats. The etiology of type 1 diabetes in dogs is multifactorial, and likely involves genetic factors, and poorly understood environmental factors, which trigger β-cell injury and inflammation. As in humans, there is a seasonal influence with the incidence peaking in winter. Environmental factors such as such as chronic insulin resistance secondary to glucocorticoid administration or obesity, and diseases which antagonize insulin’s actions would be expected to hasten onset of clinical signs when superimposed on a reduced capacity to secrete insulin as a result of immune-mediated β-cell destruction.
Type 2 diabetes is characterized by insulin resistance with concomitant β–cell dysfunction. In developed countries, the majority of feline diabetics are type 2. Insulin resistance is multifactorial and associated with genetic factors, obesity, physical inactivity, male gender, and glucocorticoid steroids.
Doctors and scientists take part in many kinds of research studies. Clinical research helps researchers understand how best to treat patients or helps them learn more about a particular condition or disease. There are many different forms of clinical research. One common form is a clinical trial. In a clinical trial, researchers test new drugs, medical devices or treatments.
Clinical trials may seek to discover new drugs, new ways of giving patients approved drugs, new combinations of approved drugs, new surgical techniques, devices, or biological products. Clinical trials are also conducted to test cutting-edge and novel therapies, like studies that involve gene therapy or gene transfer.
Informed consent is a process that helps you learn about the research study. After learning about the study, you will be able to ask the researcher or his/her staff questions. You should only agree to take part after you clearly understand the study and feel comfortable. You should take time to talk over your decision with your doctors, family, and friends. If you agree to take part, you will be asked to sign an "informed consent form."
You may consider having your pet participate in a study because:
You might consider not taking part in a study because:
There is no guarantee that a clinical trial will help your pet’s condition, but the results will contribute to knowledge that may make a difference in the future care of patients.
Clinical trials test new drugs, devices, or treatments. In some cases, taking part will not cost you anything. In other studies, the research team may bill you for drugs, devices, and services they provide. The study informed consent form will describe any costs to you in detail. If the information in the consent form is not clear, you should ask the research team to explain any costs before you sign the consent form.
Your pet is protected first and foremost by being told honestly and without bias what the known and potential risks are for participating in the trial. This information will be submitted to you in a language you will be able to understand. There is an Institutional Review Board (IRB) requirement that every participant in a clinical trial be informed about the possible risks, benefits and available alternatives. All of the information necessary to assist you in determining whether or not your pet should participate in a clinical trial is provided in a document called the "informed consent document." This document informs you of how to let the investigator know if you think your pet is experiencing a problem with the research and what resources are available to help you. You should ask any questions you may have about a clinical trial before signing the informed consent document. Even after you have signed the informed consent document to have your pet participate in a clinical trial, you should always speak to the investigator if you have questions or problems.
The Institutional Review Board (IRB) protects people and animals in research studies. The IRB includes scientists, non-scientists, and community members. The IRB reviews, approves, and monitors all in which pets take part. This oversight keeps risks to research participants as low as possible. The IRB also keeps track of ongoing studies to make sure they are being done in the right way.
This varies by study and will be covered in your Informed Consent Document.
Generally, participation ends when the study ends because it might not be safe or effective to continue treatment based on what is known at the time. Sometimes patients can remain on the study drug if they are responding to the new treatment; however, this is the exception rather than the rule.